Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer antihypertensive agents.

A M Rey1, K Grauer, J G Gums

  • 1College of Pharmacy, University of Florida, Gainesville.

Postgraduate Medicine
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subradiance of multilevel fermionic atoms in arrays with filling <math><mrow><mi>n</mi> <mo>⩾</mo> <mn>2</mn></mrow></math>.

Physical review. A·2026
Same author

Entanglement Generation in Weakly Driven Arrays of Multilevel Atoms via Dipolar Interactions.

Physical review letters·2024
Same author

Exploiting Nonclassical Motion of a Trapped Ion Crystal for Quantum-Enhanced Metrology of Global and Differential Spin Rotations.

Physical review letters·2024
Same author

Dipole-Dipole Frequency Shifts in Multilevel Atoms.

Physical review letters·2021
Same author

Detecting Out-of-Time-Order Correlations via Quasiadiabatic Echoes as a Tool to Reveal Quantum Coherence in Equilibrium Quantum Phase Transitions.

Physical review letters·2021
Same author

Dark States of Multilevel Fermionic Atoms in Doubly Filled Optical Lattices.

Physical review letters·2019
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
Same journal

Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.

Postgraduate medicine·2026
Same journal

Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study.

Postgraduate medicine·2026
See all related articles

New antihypertensive agents like betaxolol hydrochloride and doxazosin mesylate offer once-daily dosing for hypertension management. Novel drug delivery systems for verapamil hydrochloride and nifedipine also improve patient compliance and tolerability.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Hypertension management requires effective antihypertensive agents.
  • Continuous innovation in drug formulation and delivery is crucial for improving patient outcomes.
  • The development of new therapeutic options aims to enhance efficacy, safety, and patient adherence.

Purpose of the Study:

  • To review recent advancements in antihypertensive pharmacotherapy.
  • To highlight newly approved antihypertensive agents and drug delivery systems.
  • To discuss their potential benefits in clinical practice.

Main Methods:

  • Review of recently approved antihypertensive medications.
  • Analysis of pharmacological properties and clinical trial data.

Related Experiment Videos

  • Evaluation of new drug delivery systems for improved dosing and tolerability.

    • Main Results:

    • Betaxolol hydrochloride (Kerlone) offers 24-hour efficacy as a once-daily beta blocker.
    • Penbutolol sulfate (Levatol) demonstrates comparable effectiveness to existing beta blockers and diuretics.
    • Doxazosin mesylate (Cardura), a selective alpha 1 blocker, allows once-daily dosing and shows positive effects on lipid profiles.
    • New delivery systems for verapamil hydrochloride (Verelan) and extended-release nifedipine (Procardia XL) enable less frequent administration.

    Conclusions:

    • Newly approved antihypertensive agents and advanced drug delivery systems provide valuable options for hypertension treatment.
    • Once-daily dosing regimens can improve patient compliance and potentially reduce side effects.
    • These advancements contribute to more effective and patient-centered management of hypertension.